SIRT1, A calorie restriction mimetic, in a new therapeutic approach for type 2 diabetes mellitus and diabetic vascular complications

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 10, Issue 1, 2010, Pages 16-24

  Kume, Shinji ^a,b   Takashi, Uzu ^a   Atsunori, Kashiwagi ^a   Daisuke, Koya ^b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Calorie restriction; CR mimetics; Diabetes; SIRT1 activator; Sirtuins; Vascular complications

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ANTIDIABETIC AGENT; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SILENT INFORMATION REGULATOR PROTEIN 2; SIRTUIN; SIRTUIN 1;

ADIPOSE TISSUE; AGING; APOPTOSIS; CALORIC RESTRICTION; DIABETIC ANGIOPATHY; DRUG TARGETING; ENDOTHELIUM CELL; FATTY LIVER; GENE OVEREXPRESSION; GLUCOSE HOMEOSTASIS; HUMAN; LIPID METABOLISM; LIVER; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SKELETAL MUSCLE; TRANSGENIC MOUSE;

EID: 77950834672     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153010790827957     Document Type: Review

References (76)

1. Flegal, K.M.; Graubard, B.I.; Williamson, D.F. and Gail, M.H. (2007) Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA, 298, 2028-2037.
2. Yusuf, S.; Hawken, S.; Ounpuu, S.; Bautista, L.; Franzosi, M.G.;Commerford, P.; Lang, C.C.; Rumboldt, Z.; Onen, C.L.; Lisheng, L.; Tanomsup, S.; Wangai, P. Jr.; Razak, F.; Sharma, A.M. and Anand, S.S. (2005) Obesity and the risk of myocardial infarction in27,000 participants from 52 countries: a case-control study. Lancet, 366, 1640-1649.
3. Ogden, C.L.; Carroll, M.D.; Curtin, L.R.; McDowell, M.A.; Tabak,C.J. and Flegal, K.M. (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA, 295, 1549-1555
4. Cooper, M.E.; Bonnet, F.; Oldfield, M. and Jandeleit-Dahm, K.(2001) Mechanisms of diabetic vasculopathy: an overview. Am. J. Hypertens., 14, 475-486.
5. Stamler, J.; Vaccaro, O.; Neaton, J.D. and Wentworth, D. (1993)Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16, 434-444.
6. Clark, C.M.Jr. and Lee, D.A. (1995) Prevention and treatment of thecomplications of diabetes mellitus. N. Engl. J. Med., 332, 1210-1217.
7. Ness, J.; Nassimiha, D.; Feria, M.I. and Aronow, W.S. (1999) Diabetes mellitus in older African-Americans, Hispanics, and whites in an academic hospital-based geriatrics practice. Coronary Artery Dis., 10, 343-346.
8. Siitonen, O.I.; Niskanen, L.K.; Laakso, M.; Siitonen, J.T. and Pyorala,K. (1993) Lower-extremity amputations in diabetic and nondiabetic patients: a population-based study in eastern Finland.Diabetes Care, 16, 16-20.
9. From the Centers for Disease Control and Prevention. (1996)Blindness caused by diabetes--Massachusetts, 1987-1994. JAMA,276, 1865-1866.
10. Weindruch, R. and Sohal, R.S. (1997) Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N.Engl. J. Med., 337, 986-994.
11. Masoro, E.J. (2005) Overview of caloric restriction and ageing.Mech. Ageing Dev., 126, 913-922.
12. Johnson, T.E. (2006) Recent results: biomarkers of aging. Exp.Gerontol., 41, 1243-1246.
13. Heilbronn, L.K.; de Jonge, L.; Frisard, M.I.; DeLany, J.P.; Larson-Meyer, D.E.; Rood, J.; Nguyen, T.; Martin, C.K.; Volaufova, J.;Most, M.M.; Greenway, F.L.; Smith, S.R.; Deutsch, W.A.;Williamson, D.A. and Ravussin, E. (2006) Effect of 6-monthcalorie restriction on biomarkers of longevity, metabolic adaptation,and oxidative stress in overweight individuals: a randomized controlled trial. JAMA, 295, 1539-1548.
14. Weiss, E.P.; Racette, S.B.; Villareal, D.T.; Fontana, L.; Steger-May, K.; Schechtman, K.B.; Klein, S. and Holloszy, J.O. (2006) Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am. J. Clin. Nutr., 84, 1033-1042.
15. Guarente, L. and Picard, F. (2005) Calorie restriction--the SIR2 connection. Cell, 120, 473-482.
16. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.;Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.;Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang,M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.;Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram,D.K.; de Cabo, R. and Sinclair, D.A. (2006) Resveratrol improveshealth and survival of mice on a high-calorie diet. Nature, 444,337-342.
17. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin,C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.;Geny, B.; Laakso, M.; Puigserver, P. and Auwerx, J. (2006) Resveratrol improves mitochondrial function and protects againstmetabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127,1109-1122.
18. Bordone, L.; Motta, M.C.; Picard, F.; Robinson, A.; Jhala, U.S.;Apfeld, J.; McDonagh, T.; Lemieux, M.; McBurney, M.; Szilvasi,A.; Easlon, E.J.; Lin, S.J. and Guarente, L. (2006) Sirt1 regulatesinsulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol., 4, e31.
19. Moynihan, K.A.; Grimm, A.A.; Plueger, M.M.; Bernal-Mizrachi,E.; Ford, E.; Cras-Meneur, C.; Permutt, M.A. and Imai, S. (2005) Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab., 2, 105-117.
20. Picard, F.; Kurtev, M.; Chung, N.; Topark-Ngarm, A.; Senawong,T.; Machado De Oliveira, R.; Leid, M.; McBurney, M.W. and Guarente, L. (2004) Sirt1 promotes fat mobilization in white adipocytesby repressing PPAR-gamma. Nature, 429, 771-776.
21. Rodgers, J.T.; Lerin, C.; Haas, W.; Gygi, S.P.; Spiegelman, B.M.and Puigserver, P. (2005) Nutrient control of glucose homeostasisthrough a complex of PGC-1alpha and SIRT1. Nature, 434, 113-118.
22. Frye, R.A. (2000) Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun., 273, 793-798.
23. Michishita, E.; Park, J.Y.; Burneskis, J.M.; Barrett, J.C. and Horikawa, I. (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol.Biol. Cell, 16, 4623-4635.
24. Frye, R.A. (1999) Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolizeNAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun., 260, 273-279.
25. North, B.J.; Marshall, B.L.; Borra, M.T.; Denu, J.M. and Verdin, E.(2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell, 11, 437-444.
26. Shi, T.; Wang, F.; Stieren, E. and Tong, Q. (2005) SIRT3, a mitochondrialsirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem., 280, 13560-13567.
27. Vaziri, H.; Dessain, S.K.; Ng Eaton, E.; Imai, S.I.; Frye, R.A. and Pandita, T.K.; Guarente, L. and Weinberg, R.A. (2001) (hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 107, 149-159.
28. Haigis, M.C.; Mostoslavsky, R.; Haigis, K.M.; Fahie, K.; Christodoulou, D.C.; Murphy, A.J.; Valenzuela, D.M.; Yancopoulos, G.D.; Karow, M.; Blander, G.; Wolberger, C.; Prolla, T.A.; Weindruch, R.; Alt, F.W. and Guarente, L. (2006) SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell, 126, 941-954.
29. Liszt, G.; Ford, E.; Kurtev, M. and Guarente, L. (2005) Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. J. Biol. Chem., 280, 21313-21320.
30. Cheng, H.L.; Mostoslavsky, R.; Saito, S.; Manis, J.P.; Gu, Y.;Patel, P.; Bronson, R.; Appella, E.; Alt, F.W. and Chua, K.F. (2003) Developmental defects and p53 hyperacetylation in Sir2homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. USA, 100, 10794-10799.
31. McBurney, M.W.; Yang, X.; Jardine, K.; Hixon, M.; Boekelheide,K.; Webb, J.R.; Lansdorp, P.M. and Lemieux, M. (2003) The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol. Cell Biol., 23, 38-54.
32. Sequeira, J.; Boily, G.; Bazinet, S.; Saliba, S.; He, X.; Jardine, K.; Kennedy, C.; Staines, W.; Rousseaux, C.; Mueller, R. and McBurney, M.W. (2008) sirt1-null mice develop an autoimmunelike condition. Exp. Cell Res., 314, 3069-3074.
33. Boily, G.; Seifert, E.L.; Bevilacqua, L.; He, X.H.; Sabourin, G.;Estey, C.; Moffat, C.; Crawford, S.; Saliba, S.; Jardine, K.; Xuan, J.; Evans, M.; Harper, M.E. and McBurney, M.W. (2008) SirT1 regulates energy metabolism and response to caloric restriction inmice. PLoS ONE, 3, e1759.
34. Bordone, L.; Cohen, D.; Robinson, A.; Motta, M.C.; van Veen, E.; Czopik, A.; Steele, A.D.; Crowe, H.; Marmor, S.; Luo, J.; Gu, W. and Guarente, L. (2007) SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell, 6, 759-767.
35. Sun, C.; Zhang, F.; Ge, X.; Yan, T.; Chen, X.; Shi, X. and Zhai, Q. (2007) SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab., 6, 307-319.
36. Kitamura, Y.I.; Kitamura, T.; Kruse, J.P.; Raum, J.C.; Stein, R.;Gu, W. and Accili, D. (2005) FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab., 2, 153-163.
37. Qiao, L. and Shao, J. (2006) SIRT1 regulates adiponectin geneexpression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J. Biol. Chem., 281, 39915-39924.
38. Qiang, L.; Wang, H. and Farmer, S.R. (2007) Adiponectin secretionis regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol. Cell Biol., 27, 4698-4707.
39. Kadowaki, T.; Yamauchi, T.; Kubota, N.; Hara, K.; Ueki, K. and Tobe, K. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest., 116, 1784-1792.
40. Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K.; Mori, Y.; Ide, T.; Murakami, K.; Tsuboyama-Kasaoka, N.; Ezaki, O.; Akanuma, Y.; Gavrilova, O.; Vinson, C.; Reitman, M.L.; Kagechika, H.; Shudo, K.; Yoda, M.; Nakano, Y.; Tobe, K.;Nagai, R.; Kimura, S.; Tomita, M.; Froguel, P. and Kadowaki, T. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 7,941-946.
41. Zhu, M.; Miura, J.; Lu, L.X.; Bernier, M.; DeCabo, R.; Lane, M.A.; Roth, G.S. and Ingram, D.K. (2004) Circulating adiponectin levels increase in rats on caloric restriction: the potential for insulin sensitization. Exp. Gerontol., 39, 1049-1059.
42. Finck, B.N. and Kelly, D.P. (2006) PGC-1 coactivators: inducibleregulators of energy metabolism in health and disease. J. Clin. Invest., 116, 615-622.
43. Gerhart-Hines, Z.; Rodgers, J.T.; Bare , O.; Lerin, C.; Kim, S.H.;Mostoslavsky, R.; Alt, F.W.; Wu, Z. and Puigserver, P. (2007) Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J., 26, 1913-1923.
44. Milne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.;Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; Bemis, J.E.; Xie, R.; Disch, J.S.; Ng, P.Y.; Nunes, J.J.; Lynch, A.V.; Yang, H.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medvedik, O.; Sinclair, D.A.; Olefsky, J.M.; Jirousek, M.R.; Elliott, P.J. and Westphal, C.H. (2007) Small molecule activatorsof SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 450, 712-716.
45. Liu, Y.; Dentin, R.; Chen, D.; Hedrick, S.; Ravnskjaer, K.; Schenk, S.; Milne, J.; Meyers, D.J.; Cole, P.; Iii, J.Y.; Olefsky, J.; Guarente, L. and Montminy, M. (2008) A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature, 456,269-273.
46. Hou, X.; Xu, S.; Maitland-Toolan, K.A.; Sato, K.; Jiang, B.; Ido, Y.; Lan, F.; Walsh, K.; Wierzbicki, M.; Verbeuren, T.J. and Cohen, R.A. (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem., 283(29),20015-20026.
47. Pfluger, P.T.; Herranz, D.; Velasco-Miguel, S.; Serrano, M. and Tschop, M.H. (2008) Sirt1 protects against high-fat dietinduced metabolic damage. Proc. Natl. Acad. Sci. USA, 105, 9793-9798.
48. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.;Frye, R.A. and Mayo, M.W. (2004) Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 23, 2369-2380.
49. Yang, S.R.; Wright, J.; Bauter, M.; Seweryniak, K.; Kode, A.and Rahman, I. (2007) Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications forchronic inflammation and aging. Am. J. Physiol. Lung Cell Mol. Physiol., 292, L567-576.
50. Csiszar, A.; Labinskyy, N.; Podlutsky, A.; Kaminski, P.M.;Wolin, M.S.; Zhang, C.; Mukhopadhyay, P.; Pacher, P.; Hu, F.; de Cabo, R.; Ballabh, P. and Ungvari, Z. (2008) Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am. J. Physiol. Heart Circ. Physiol., 294, H2721-H2735.
51. Bosutti, A.; Malaponte, G.; Zanetti, M.; Castellino, P.; Heer, M.; Guarnieri, G. and Biolo, G. (2008) Calorie restriction modulates inactivity-induced changes in the inflammatory markers C-reactive protein and pentraxin-3. J. Clin. Endocrinol. Metab., 93, 3226-3229.
52. Walford, R.L.; Mock, D.; Verdery, R. and MacCallum, T. (2002)Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J. Gerontol. A. Biol. Sci. Med. Sci., 57,B211-224.
53. Fontana, L.; Meyer, T.E.; Klein, S. and Holloszy, J.O. (2004)Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl. Acad. Sci. USA, 101,6659-6663.
54. Raitakari, M.; Ilvonen, T.; Ahotupa, M.; Lehtimaki, T.; Harmoinen, A.; Suominen, P.; Elo, J.; Hartiala, J. and Raitakari, O.T. (2004) Weight reduction with very-low-caloric diet and endothelial function in overweight adults: role of plasma glucose. ArteriosclerThromb. Vasc. Biol., 24, 124-128.
55. Mattagajasingh, I.; Kim, C.S.; Naqvi, A.; Yamamori, T.; Hoffman,T.A.; Jung, S.B.; DeRicco, J.; Kasuno, K. and Irani, K. (2007) SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci.USA, 104, 14855-14860.
56. Zhang, Q.J.; Wang, Z.; Chen, H.Z.; Zhou, S.; Zheng, W.; Liu, G.;Wei, Y.S.; Cai, H.; Liu, D.P. and Liang, C.C. (2008) Endotheliumspecific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc. Res., 80, 191-199.
57. Verzola, D.; Gandolfo, M.T.; Ferrario, F.; Rastaldi, M.P.;Villaggio, B.; Gianiorio, F.; Giannoni, M.; Rimoldi, L.; Lauria, F.;Miji, M.; Deferrari, G. and Garibotto, G. (2007) Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int.,72, 1262-1272.
58. Kume, S.; Haneda, M.; Kanasaki, K.; Sugimoto, T.; Araki, S.;Isono, M.; Isshiki, K.; Uzu, T.; Kashiwagi, A. and Koya, D. (2006) Silent information regulator 2 (SIRT1) attenuates oxidative stressinduced mesangial cell apoptosis via p53 deacetylation. FreeRadic. Biol. Med., 40, 2175-2182.
59. Kume, S.; Haneda, M.; Kanasaki, K.; Sugimoto, T.; Araki, S.; Isshiki, K.; Isono, M.; Uzu, T.; Guarente, L.; Kashiwagi, A. and Koya, D. (2007) SIRT1 inhibits transforming growth factor betainduced apoptosis in glomerular mesangial cells via Smad7 deacetylation.J. Biol. Chem., 282, 151-158.
60. Haneda, M.; Koya, D.; Isono, M. and Kikkawa, R. (2003) Overviewof glucose signaling in mesangial cells in diabetic nephropathy. J. Am. Soc. Nephrol., 14, 1374-1382.
61. Kitada, M.; Koya, D.; Sugimoto, T.; Isono, M.; Araki, S.;Kashiwagi, A. and Haneda, M. (2003) Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes, 52,2603-2614.
62. Dong, F. and Ren, J. (2007) Fidarestat improves cardiomyocytecontractile function in db/db diabetic obese mice through a histone deacetylase Sir2-dependent mechanism. J. Hypertens., 25, 2138-2147.
63. Alcendor, R.R.; Kirshenbaum, L.A.; Imai, S.; Vatner, S.F. andSadoshima, J. (2004) Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ. Res., 95, 971-980.
64. Alcendor, R.R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.;Tian, B.; Wagner, T.; Vatner, S.F. and Sadoshima, J. (2007) Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res., 100, 1512-1521.
65. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu S, Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B. and Sinclair, D.A. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature,425, 191-196.
66. Wood, J.G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S.L.; Tatar,M. and Sinclair, D. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 430, 686-689
67. Jarolim, S.; Millen, J.; Heeren, G.; Laun, P.; Goldfarb, D.S. andBreitenbach, M. (2004) A novel assay for replicative lifespan in Saccharomyces cerevisiae. FEMS Yeast Res., 5, 169-177.
68. Viswanathan, M.; Kim, S.K.; Berdichevsky, A. and Guarente, L.(2005) A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev. Cell, 9, 605-615.
69. Valenzano, D.R.; Terzibasi, E.; Genade, T.; Cattaneo, A.;Domenici, L. and Cellerino, A. (2006) Resveratrol prolongs lifespan and retards the onset of age-related markers in a shortlived vertebrate. Curr. Biol., 16, 296-300.
70. Kumar, A.; Kaundal, R.K.; Iyer, S. and Sharma, S.S. (2007) Effects ofresveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci., 80, 1236-1244.
71. Ates, O.; Cayli, S.R.; Yucel, N.; Altinoz, E.; Kocak, A.; Durak, M.A.; Turkoz, Y. and Yologlu, S. (2007) Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J. Clin. Neurosci., 14, 256-260.
72. Thirunavukkarasu, M.; Penumathsa, S.V.; Koneru, S.; Juhasz, B.;Zhan, L.; Otani, H.; Bagchi, D.; Das, D.K. and Maulik, N. (2007) Resveratrol alleviates cardiac dysfunction in streptozotocininduced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase.Free Radic. Biol. Med., 43, 720-729.
73. Zang, M.; Xu, S.; Maitland-Toolan, K.A.; Zuccollo, A.; Hou, X.; Jiang, B.; Wierzbicki, M.; Verbeuren, T.J. and Cohen, R.A. (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptordeficientmice. Diabetes, 55, 2180-2191.
74. Revollo, J.R.; Grimm, A.A. and Imai, S. (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem., 279, 50754-50763.
75. Wang, T.; Zhang, X.; Bheda, P.; Revollo, J.R.; Imai, S. andWolberger, C. (2006) Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat. Struct. Mol. Biol., 13,661-662.
76. Fulco, M.; Cen, Y.; Zhao, P.; Hoffman, E.P.; McBurney, M.W.; Sauve, A.A. and Sartorelli, V. (2008) Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev. Cell, 14, 661-673.